Oramed Pharmaceuticals Inc.
Income Statement
| Line Item | FY2025 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $1.3M | $2.7M | $2.7M | $2.7M | $2.7M | $2.4M | $2.5M |
| Cost of Revenue | $2.0M | — | — | — | — | $90.0K | $-86.0K | $187.0K |
| Gross Profit | $13.0K | — | — | — | — | $2.6M | $2.5M | $2.3M |
| Gross Margin | 0.7% | — | — | — | — | 96.7% | 103.5% | 92.4% |
| Operating Expenses | ||||||||
| Research & Development | $6.4M | $9.0M | $27.6M | $21.0M | $10.2M | $13.5M | $12.0M | $10.3M |
| SG&A Expense | $8.7M | $8.4M | $13.8M | $5.9M | $4.2M | $3.7M | $4.1M | $2.8M |
| Operating Income | $-15.1M | $-15.8M | $-40.6M | $-24.2M | $-11.8M | $-14.6M | $-13.5M | $-10.8M |
| Operating Margin | -754.4% | -1,176.8% | -1,502.0% | -896.2% | -433.8% | -541.3% | -552.3% | -438.6% |
| Interest Expense | — | $2.0M | — | — | — | — | — | — |
| Pretax Income | $75.3M | $5.1M | $-37.7M | — | $-11.5M | $-14.1M | $-12.7M | $-10.1M |
| Income Tax Expense | $11.3M | — | $100.0K | — | — | $300.0K | — | $400.0K |
| Net Income | $64.1M | $5.1M | $-36.6M | $-23.0M | $-11.5M | $-14.4M | $-12.7M | $-10.5M |
| Net Margin | 3,202.5% | 379.7% | -1,352.6% | -850.5% | -424.8% | -531.1% | -519.7% | -426.7% |
| EPS (Basic) | $1.53 | $0.14 | $-0.94 | $0.78 | $0.56 | $0.82 | $0.86 | $0.79 |
| EPS (Diluted) | $1.50 | $0.14 | $-0.94 | $0.78 | $0.56 | $0.82 | $0.86 | $0.79 |
| Shares Outstanding (Basic) | 41.4M | 40.3M | 39.0M | 38.2M | 23.7M | 17.4M | 17.4M | 14.3M |
| Shares Outstanding (Diluted) | 42.4M | 40.6M | 39.0M | 38.2M | 23.7M | 17.4M | 17.4M | 14.3M |
| Dividends Per Share | $0.25 | — | — | — | — | — | — | — |